Francisco Silva - Feb 13, 2024 Form 4 Insider Report for BioRestorative Therapies, Inc. (BRTX)

Role
VP of Research and Development, Director, 10%+ Owner
Signature
/s/ Francisco Silva
Stock symbol
BRTX
Transactions as of
Feb 13, 2024
Transactions value $
$0
Form type
4
Date filed
2/15/2024, 04:13 PM
Previous filing
Aug 31, 2023
Next filing
Mar 20, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding BRTX Common Stock 165K Feb 13, 2024 Direct F1
holding BRTX Common Stock 12.1K Feb 13, 2024 IRA

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BRTX Stock Option Award $0 +395K $0.00 395K Feb 13, 2024 Common Stock 395K $1.45 Direct F5
holding BRTX Stock Option 3 Feb 13, 2024 Common Stock 3 $3,000.00 Direct F2
holding BRTX Stock Option 1 Feb 13, 2024 Common Stock 1 $3,000.00 Direct
holding BRTX Stock Option 9 Feb 13, 2024 Common Stock 9 $3,000.00 Direct F2
holding BRTX Stock Option 6 Feb 13, 2024 Common Stock 6 $3,000.00 Direct F2
holding BRTX Stock Option 15 Feb 13, 2024 Common Stock 15 $3,000.00 Direct F2
holding BRTX Stock Option 20 Feb 13, 2024 Common Stock 20 $3,000.00 Direct F2
holding BRTX Stock Option 25 Feb 13, 2024 Common Stock 25 $3,000.00 Direct F2
holding BRTX Stock Option 293K Feb 13, 2024 Common Stock 293K $5.08 Direct F2
holding BRTX Stock Option 42.1K Feb 13, 2024 Common Stock 42.1K $5.08 Direct F3
holding BRTX Stock Option 107K Feb 13, 2024 Common Stock 107K $2.91 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 48,912 shares received pursuant to an unvested restricted stock unit grant. Such shares vest on March 18, 2024.
F2 The option is currently exercisable.
F3 The option vests and becomes exercisable to the extent of 21,030 shares on November 4, 2021 and 21,029 shares in eight nearly equal quarterly installments beginning November 4, 2022 and continuing every three months thereafter until fully vested.
F4 The option vests and becomes exercisable to the extent of 53,381 shares on February 17, 2023 and 53,381 shares in eight nearly equal quarterly installments beginning February 17, 2024 and continuing every three months thereafter until fully vested.
F5 The option vests and becomes exercisable to the extent of 197,369 shares on February 13, 2024 and 197,368 shares in eight nearly equal quarterly installments beginning February 13, 2025 and continuing every three months thereafter until fully vested.